A new approach to antimalarial development, aided by high-throughput screening, could help to overcome resistance.
Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements in cutaneous lupus erythematosus (CLE) skin disease ...
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for litifilimab (BIIB059) for the ...
thesun.ng on MSN
On Ataben’s contributions to neurological studies in Nigeria
By Grateful OgunjebeOn December 23, 2025, an article titled ‘Neurologist raises the alarm over rising stroke cases among ...
The Trump administration released the next 15 drugs subject to Medicare price negotiation, including for the first time ...
Fungal infections are becoming deadlier as drug resistance spreads and treatment options stall. Researchers at McMaster University discovered that a molecule called butyrolactol A can dramatically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results